Evidence map›Paper›PMID 38018694›Full record

ArticlePharmacology research & perspectives2023

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB

Monica Patel, Natasha L Grimsey, Samuel D Banister, David B Finlay, Michelle Glass

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Side-Chain Homologs of ΔMolecular neurobiology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Monica PatelDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0003-2686-7246
Natasha L GrimseyDepartment of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.ORCID 0000-0003-3941-4537
Samuel D BanisterLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, University of Sydney, New South Wales, Australia.ORCID 0000-0002-4690-4318
David B FinlayDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-3160-2931
Michelle GlassDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-5997-6898
University of Otago · NZThe University of Sydney · AUUniversity of Auckland · NZ

Funding

Health Research Council of New ZealandUniversity of Otago Doctoral Scholarship
6 · The paper itself

Abstract

The rapid structural evolution and emergence of novel synthetic cannabinoid receptor agonists (SCRAs) in the recreational market remains a key public health concern. Despite representing one of the largest classes of new psychoactive substances, pharmacological data on new SCRAs is limited, particularly at the cannabinoid CB

Indexed as

Cannabinoid Receptor AgonistsCannabinoidsHEK293 CellsHumansLigandsReceptors, CannabinoidCannabinoid Receptor AgonistsCannabinoidsLigandsReceptors, Cannabinoidagonist biascannabinoid CB2 receptorcell signalingsynthetic cannabinoid receptor agonistTHC

Identifiers

PMID38018694
PMCPMC10685394
OpenAlexW4389141112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.